CRISPR/Cas9 Edition of the F9 Gene in Human Mesenchymal Stem Cells for Hemophilia B Therapy

Irving Jair Lara-Navarro, Luis Felipe Jave-Suárez, Juan Antonio Marchal, Ana Rebeca Jaloma-Cruz, Eleni Gavriilaki · 2024

Read CRISPR/Cas9 Edition of the F9 Gene in Human Mesenchymal Stem Cells for Hemophilia B Therapy by Irving Jair Lara-Navarro, Luis Felipe Jave-Suárez, Juan Antonio Marchal, Ana Rebeca Jaloma-Cruz, Eleni Gavriilaki (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11676118.txt.

Description

Irving Jair Lara-Navarro and co-authors describe lab work from 2024 on gene editing as a route to treat hemophilia B. People with the illness lack a blood factor that helps clots form. Shots of the factor wear off fast, so a lasting fix would help.

The team used CRISPR/Cas9 to place a healthy copy of the F9 gene into human stem cells and into a test cell line. Both kinds of cells then made the missing factor, the authors report, though the stem cells took the edit less often. A virus-based test system helped check that the method worked. Next steps focus on raising how often the stem cells accept the edit.

Catalog record

CREATORIrving Jair Lara-Navarro, Luis Felipe Jave-Suárez, Juan Antonio Marchal, Ana Rebeca Jaloma-Cruz, Eleni Gavriilaki
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE21 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11676118

Browse the full library · About the Tower of Babel